ReviewLiver international : official journal of the International Association for the Study of the Liver2008
Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets.
Review in Liver international : official journal of the International Association for the Study of the Liver, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Emerging omics diagnosis of perihilar cholangiocarcinoma.Journal of gastroenterology · 2026Article
- Clonorchis sinensis and cholangiocarcinoma: molecular mechanisms and biomarker advances.Parasite (Paris, France) · 2026Review
- Regulatory mechanisms and clinical implications of PIWI-interacting RNAs (piRNAs) in major digestive tract cancers.Cancer cell international · 2025Review
- Occupational and Environmental Cholangiocarcinoma-Related Toxic Exposures.GE Portuguese journal of gastroenterology · 2025Review
- Hepatic Nuclear Receptors in Cholestasis-to-Cholangiocarcinoma Pathology.The American journal of pathology · 2025Review
- The role and implication of autophagy in cholangiocarcinoma.Cell death discovery · 2023Review
- DNA methylation in cell plasticity and malignant transformation in liver diseases.Pharmacology & therapeutics · 2023Review
- NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.Gastroenterology · 2022Article
- Cholangiocarcinoma and liver transplantation: What we know so far?World journal of gastrointestinal pathophysiology · 2021Review
- NcRNAs and Cholangiocarcinoma.Journal of Cancer · 2018Review
- Recent Advances in Understanding Cholangiocarcinoma.F1000Research · 2017Review
- Review
- The significance of genetics for cholangiocarcinoma development.Annals of translational medicine · 2013Review
- Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer.Journal of molecular biomarkers & diagnosis · 2013Article
- Genetic profiling of intrahepatic cholangiocarcinoma.Current opinion in gastroenterology · 2012Review
- Molecular pathogenesis of cholangiocarcinoma.International journal of hepatology · 2012Article
- Comparison of KRAS mutation analysis and FISH for detecting pancreatobiliary tract cancer in cytology specimens collected during endoscopic retrograde cholangiopancreatography.The Journal of molecular diagnostics : JMD · 2010Article
- Low doses of the carcinogen furan alter cell cycle and apoptosis gene expression in rat liver independent of DNA methylation.Environmental health perspectives · 2010Article
- Aberrant DNA methylation profile in cholangiocarcinoma.World journal of gastrointestinal pathophysiology · 2010Article
- Molecular mechanisms of cholangiocarcinoma.World journal of gastrointestinal pathophysiology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cholangiocarcinomas (CCs) are highly lethal malignant tumours arising from the biliary tract epithelium. The disease is notoriously difficult to diagnose and is usually fatal because of its typically late clinical presentation and the lack of effective non-surgical therapeutic modalities. The overall survival rate, including resected patients is poor, with less than 5% of patients surviving 5 years, a rate which has not changed significantly over the past 30 years. Although CC is a relatively uncommon tumor, interest in this disease is rising as incidence and mortality rates for intrahepatic cholangiocarcinoma are increasing markedly worldwide. A variety of risk factors, including primary sclerosing cholangitis, liver fluke infestation, and hepatolithiasis have been described. However, for most CCs the cause is unknown, and affected individuals have no history of exposure to, or association with, known risk factors. Recent advances in molecular pathogenesis have highlighted the importance of epigenetic alterations in the form of promoter region hypermethylation and histone deacetylation in addition to genetic changes in the process of cholangiocarcinogenesis. This review provides a comprehensive overview of the genes reported to be methylated in CC to date and their putative roles in cholangiocarcinogenesis. Future directions in the study of methylated genes and their potential roles as diagnostic and prognostic markers are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.